文献速递前列腺癌

镭-223治疗转移性去势抵抗性前列腺癌:美国三级肿瘤中心回顾性研究

Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-08-19

该回顾性研究纳入220例骨转移为主的mCRPC患者,评估镭-223化疗前与化疗后使用的治疗模式及总生存。结果显示化疗前使用镭-223平均注射次数更多(5.3 vs 4.3,p<0.001),但化疗前 vs 化疗后、联合 vs 单药的总生存均无显著差异。

要点

  • 化疗前使用镭-223的平均注射次数更多(5.3 vs 4.3,p<0.001)
  • 镭-223化疗前 vs 化疗后总生存无显著差异
  • 镭-223联合 vs 单药总生存无显著差异

核心结论

  • 化疗前使用镭-223可提高完成镭-223治疗的可能性。
  • 镭-223化疗前或化疗后使用、联合或单药使用均未导致总生存的显著差异。

研究设计与样本

  • 回顾性研究,纳入220例骨转移为主的mCRPC患者,均接受镭-223治疗。
  • 按镭-223使用时机分为化疗前(64例)、化疗后(83例)和未化疗(73例)三组。

主要发现

  • 化疗前组平均镭-223注射次数为5.3次,化疗后组为4.3次(p<0.001)。
  • 化疗前或化疗后给予化疗的周期数相似。
  • 镭-223作为mCRPC治疗的平均线数在化疗前组为第3线,化疗后组为第5线(p<0.001)。
  • 41.8%的患者接受镭-223联合其他mCRPC治疗,常见为阿比特龙(43.5%)或恩扎卢胺(52.2%)。
  • 从首次mCRPC治疗起的中位总生存:化疗前组39.4个月(95%CI 33.0–48.8),化疗后组37.4个月(95%CI 32.0–43.5);联合治疗组35.2个月(95%CI 27.9–43.3),单药组32.0个月(95%CI 26.9–36.0)。

临床怎么用

  • 在临床实践中,镭-223用于化疗前可能提高治疗完成率,但需结合患者个体情况。
  • 镭-223联合其他mCRPC治疗(如阿比特龙或恩扎卢胺)是常见模式,但总生存未见显著获益。

局限性

  • 回顾性研究设计可能存在选择偏倚。
  • 样本来自单一学术中心,结果外推需谨慎。
  • 未提供统计学显著性检验的具体P值(除注射次数和线数外)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guidelines for optimal sequencing of radium-223 and chemotherapy for metastatic castration resistant prostate cancer (mCRPC) do not exist. This study evaluated treatment patterns and overall survival (OS) among patients with mCRPC treated with radium-223 in an academic clinical setting. METHODS: A retrospective study was conducted of bone metastases-predominant mCRPC patients treated with radium-223. Treatment patterns from 2013 to 2018 were evaluated in patients treated with radium-223 pre- vs. post-chemotherapy. OS was examined using Kaplan-Meier medians and 95% confidence intervals. RESULTS: In total, 220 patients were treated with radium-223 (64 pre-chemotherapy, 83 post-chemotherapy, 73 no chemotherapy). Mean radium-223 injections per patient was 5.3 and 4.3 in the pre- vs. post-chemotherapy cohorts, respectively (p < 0.001). The number of chemotherapy cycles was similar for chemotherapy given pre- or post-radium-223. Mean line of mCRPC therapy of radium-223 was 3rd and 5th when given pre- and post-chemotherapy, respectively (p < 0.001). 41.8% patients were treated with radium-223 in combination with another mCRPC therapy, commonly abiraterone acetate (43.5%) or enzalutamide (52.2%). The majority received combination therapy for the duration of radium-223 treatment; 20.7% started another agent after radium-223 initiation; 20.7% initiated radium-223 while on established therapy. Median OS from first mCRPC treatment was 39.4 months (95% CI 33.0, 48.8) for patients with radium-223 pre-chemotherapy vs. 37.4 months (95% CI 32.0, 43.5) post-chemotherapy (and 35.2 months [95% CI 27.9, 43.3] vs. 32.0 months [95% CI 26.9, 36.0] for patients with radium-223 combination vs. monotherapy). CONCLUSIONS: This retrospective analysis of patients treated with radium-223 demonstrates that administration of radium-223 pre-chemotherapy increased likelihood of completion of radium-223 treatment. Radium-223 given pre- or post-chemotherapy and with or without combination therapy did not result in significant differences in OS. Additional studies are needed to determine the optimal sequencing strategy of mCRPC in the modern era.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. McKay RR, Silver R, Bhak RH, et al. Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center. Prostate Cancer Prostatic Dis. 2020. PMID: 32814846. doi:10.1038/s41391-020-00271-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。